An Open-Label Study to Evaluate the Safety and Efficacy of PRX-08066 in Patients With Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease
NCT00677872 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2009-07-30
Summary
A 3-month open label study to evaluate the safety and efficacy of PRX-08066 in patients with pulmonary hypertension and COPD.
Conditions
- COPD
- Pulmonary Hypertension
Interventions
- DRUG
-
PRX-08066
Sponsors & Collaborators
-
Epix Pharmaceuticals, Inc.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 40 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-05-31
- Primary Completion
- 2008-12-31
Countries
- United States
Study Locations
More Related Trials
-
Frespaciguat (MK-5475) in Participants With Pulmonary Hypertension Associated With Chronic Obstructive Pulmonary Disease (PH-COPD) (MK-5475-006)
NCT04370873 ·Status: COMPLETED ·Phase: PHASE1
-
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study With BPS-314d-MR-PAH-303 in Participants With Pulmonary Arterial Hypertension
NCT03657095 ·Status: TERMINATED ·Phase: PHASE3
-
ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
NCT00879229 ·Status: TERMINATED ·Phase: PHASE3
-
A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD)
NCT03496623 ·Status: TERMINATED ·Phase: PHASE3
-
Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD
NCT01728220 ·Status: COMPLETED ·Phase: PHASE2
-
Dose Determination Safety and Activity Study of Inhaled NX1011 to Treat Pulmonary Arterial Hypertension
NCT00323024 ·Status: WITHDRAWN ·Phase: PHASE2
-
Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis
NCT00703339 ·Status: TERMINATED ·Phase: PHASE2
-
A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension
NCT02676947 ·Status: COMPLETED ·Phase: PHASE2
-
Comparison of Vasodilator Response of Inhaled Epoprostenol and Inhaled Nitric Oxide
NCT04231084 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Single and Multiple Doses of Different Formulations of a Prostacyclin Receptor Agonist
NCT05427162 ·Status: COMPLETED ·Phase: PHASE1
-
3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF
NCT02267655 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Providing Treatment Access in Participants With Pulmonary Hypertension Completing a Parent Study and Having no Other Option
NCT05179876 ·Status: RECRUITING ·Phase: PHASE3
-
PRIMEx - A Study of 2 Doses of Oral CXA-10 in Pulmonary Arterial Hypertension (PAH)
NCT03449524 ·Status: TERMINATED ·Phase: PHASE2
-
Effects of Ventavis in Patients With Pulmonary Hypertension (PH) Secondary to Chronic Obstructive Pulmonary Disease (COPD)
NCT01437878 ·Status: TERMINATED ·Phase: PHASE2
-
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
NCT02036970 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
NCT06616974 ·Status: RECRUITING ·Phase: PHASE2
-
Single Dose Study in Patients With Chronic Obstructive Pulmonary Disease (COPD) Associated Pulmonary Hypertension.
NCT00640315 ·Status: COMPLETED ·Phase: PHASE1
-
Inhaled Treprostinil in Participants With Pulmonary Hypertension Due to Chronic Obstructive Pulmonary Disease (PH-COPD)
NCT03794583 ·Status: TERMINATED ·Phase: PHASE3
-
A Study to Assess the Safety, Tolerability, and Hemodynamic Response of PB1046 in Subjects With PAH
NCT03315507 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD
NCT03012646 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Multi-Center, Open-Label, Multiple Dose, Dose Finding Study Exploring the Safety and Tolerability of Beraprost Sodium Modified Release in PAH Patients
NCT00781885 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacogenomics in Pulmonary Arterial Hypertension
NCT00593905 ·Status: WITHDRAWN
-
Safety Surveillance of Targeted Drugs for Pulmonary Hypertension Using a Computerized Follow-up System: a Nationwide Cohort Study
NCT05372263 ·Status: RECRUITING
-
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
NCT07073820 ·Status: RECRUITING ·Phase: PHASE2